Complications of diabetes explained

Diabetes complication
Field:Endocrinology

Complications of diabetes are secondary diseases that are a result of elevated blood glucose levels that occur in diabetic patients. These complications can be divided into two types: acute and chronic. Acute complications are complications that develop rapidly and can be exemplified as diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar state (HHS), lactic acidosis (LA), and hypoglycemia. Chronic complications develop over time and are generally classified in two categories: microvascular and macrovascular. Microvascular complications include neuropathy, nephropathy, and retinopathy; while cardiovascular disease, stroke, and peripheral vascular disease are included in the macrovascular complications.[1]

The complications of diabetes can dramatically impair quality of life and cause long-lasting disability. Overall, complications are far less common and less severe in people with well-controlled blood sugar levels.[2] [3] Some non-modifiable risk factors such as age at diabetes onset, type of diabetes, gender, and genetics may influence risk. Other health problems compound the chronic complications of diabetes such as smoking, obesity, high blood pressure, elevated cholesterol levels, and lack of regular exercise. Complications of diabetes are a strong risk factor for severe COVID-19 illness.[4]

Acute complications

Diabetic ketoacidosis (DKA)

Diabetic ketoacidosis (DKA) is one of the life-threatening severe complications of diabetes that demands immediate attention and intervention. It is considered a medical emergency and can affect both patients with T1D (type 1 diabetes) and T2D (type 2 diabetes), but it is more common in T1D.[5] DKA results from significantly low insulin levels due to various factors including undiagnosed diabetes (people who did not know they have diabetes), missed or delayed doses, insufficient insulin administration, or undergoing physiological stress (e.g. infection, surgery, Stroke, or trauma).[6] [7]

Due to insulin absence, it simply triggers the release of counter-regulatory hormones resulting in serious health complications. This release prompts excessive free fatty acids (FFAs) production as a result of the adipose tissue exhibiting heightened activity of hormone-sensitive lipase. Subsequently, the liver turns fatty acid to ketone bodies for fuel, a process known as ketosis, which causes Ketonemia (high ketone level in the blood) that decreases the blood's pH, leading to DKA. While periodic ketosis is normal, but can become a serious problem if sustained. These hormones can also induce hyperglycemia (high blood glucose) by stimulating gluconeogenesis thereby increasing the renal glucose output. In addition to the endogenous renal glucose produced by the kidneys. The condition of high circulating concentrations of ketone bodies and hyperglycemia leads to osmotic diuresis, characterized by the excessive presence of glucose and ketones in the urine. Consequently, osmotic diuresis causes dehydration and electrolyte loss.[8] [9] [10]

Symptoms of DKA can be noticed within a few hours, like polyuria (excessive urine production), polydipsia (excessive thirst), Weight loss, weakness, nausea, vomiting, and deep rapid breathing (Kussmaul respiration). Moreover, abdominal pain is common and may be severe.[11] The level of consciousness is typically normal until late in the process, when lethargy may progress to coma. Ketoacidosis can easily become severe enough to cause hypotension, shock, and death. The DKA is diagnosed by the urine analysis which will reveal significant levels of ketone bodies (which have exceeded their renal threshold blood levels to appear in the urine, often before other overt symptoms). And also venous blood investigation for electrolytes, glucose, and acid-base status.

The expected result of the treatment tackles the deeper causes; which are dehydration, acidosis, and hyperglycemia, and initiates a reversal of the ketosis process. While replacing fluid and electrolyte loss, insulin, and acid-placed balance are the aim of this treatment. proper treatment usually results in full recovery, though death can result from inadequate or delayed treatment, or from complications (e.g., brain edema).

Preventing DKA is attainable by following some precautions. While feeling unwell, Start with regular monitoring of blood glucose levels. In addition to measuring blood or urine ketone concentrations twice a day and more. In case there are ketones, insulin doses should be increased. Patients are also advised to focus on dehydration and go to the hospital in case of frequent vomiting. It's essential to emphasize that insulin should never be discontinued, even if there is no intake of food or fluids. Patients' education and awareness of managing a sick day is a key element, as recognizing symptoms, and knowing when to contact a healthcare provider. This education significantly contributes to reducing the occurrence of DKA.

Hyperglycemia hyperosmolar state (HHS)

hyperosmolar non-ketotic state (HONK) or Hyperglycemia hyperosmolar state (HHS) is an acute complication sharing many symptoms with DKA, but an entirely different origin and different treatment. Oppositely, the prevalence of HHS is common in individuals with T2D. Furthermore, it showcases approximately ten times greater mortality rate than the observed in DKA.[12]

Both DKA and HHS occur when insulin becomes less effective, either due to a shortage of insulin secretion (as in DKA), or lack of proper insulin action (as in HHS). For a person with very high blood glucose levels(usually considered to be above 30 mmol/L (600 mg/dL), that will result in osmotic diuresis, water is osmotically drawn out of cells into the blood and the kidneys eventually begin to dump glucose into the urine. This results in a loss of water (which contains electrolytes and glucose) that will increase blood osmolarity.[13] If the fluid is not replaced, by mouth or intravenously, will ultimately result in dehydration (which in HHS typically becomes worse than DKA). Also causes electrolyte imbalances which are always dangerous. A decline in consciousness levels is primarily attributed to an increase in plasma osmolality. lethargy may ultimately progress to a coma which is more common in T2D than T1D.

HHS, unlike DKA, does not result in significant ketosis and acidosis, or there may be only a very minimal. This is because the presence of a small quantity of insulin suppresses the release of counterregulatory hormones and limits the production of ketones. Multiple factors can trigger HHS, including infection, myocardial infarction, and trauma, as well as infections in the respiratory, digestive, and urinary systems. Rising obesity rates and the greater consumption of high-carbohydrate beverages have both played a role in the increased incidence of HHS. Moreover, certain medications prescribed for different conditions have the potential to cause HHS. As with DKA, urgent medical treatment is necessary, commonly beginning with fluid volume replacement. On the whole, HHS is a medical emergency marked with hyperglycemia, hyperosmolarity, dehydration, and mild or no ketosis.

Hypoglycemia

Hypoglycemia, or abnormally low blood glucose, is an acute complication of several diabetes treatments.[14] It is rare otherwise, either in diabetic or non-diabetic patients. The patient may become agitated, sweaty, weak, and have many symptoms of sympathetic activation of the autonomic nervous system resulting in feelings akin to dread and immobilized panic. Consciousness can be altered or even lost in extreme cases, leading to coma, seizures, or even brain damage and death. In patients with diabetes, this may be caused by several factors, such as too much or incorrectly timed insulin, too much or incorrectly timed exercise (exercise decreases insulin requirements) or not enough food (specifically glucose containing carbohydrates). The variety of interactions makes cause identification difficult in many instances.

It is more accurate to note that iatrogenic hypoglycemia is typically the result of the interplay of absolute (or relative) insulin excess and compromised glucose counterregulation in type 1 and advanced type 2 diabetes.[15] Decrements in insulin, increments in glucagon, and, absent the latter, increments in epinephrine are the primary glucose counterregulatory factors that normally prevent or (more or less rapidly) correct hypoglycemia. In insulin-deficient diabetes (exogenous) insulin levels do not decrease as glucose levels fall, and the combination of deficient glucagon and epinephrine responses causes defective glucose counterregulation.

Furthermore, reduced sympathoadrenal responses can cause hypoglycemia unawareness. The concept of hypoglycemia-associated autonomic failure (HAAF) or Cryer syndrome[16] in diabetes posits that recent incidents of hypoglycemia causes both defective glucose counterregulation and hypoglycemia unawareness. By shifting glycemic thresholds for the sympathoadrenal (including epinephrine) and the resulting neurogenic responses to lower plasma glucose concentrations, antecedent hypoglycemia leads to a vicious cycle of recurrent hypoglycemia and further impairment of glucose counterregulation.[17] In many cases (but not all), short-term avoidance of hypoglycemia reverses hypoglycemia unawareness in affected patients, although this is easier in theory than in clinical experience.

In most cases, hypoglycemia is treated with sugary drinks or food. In severe cases, an injection of glucagon (a hormone with effects largely opposite to those of insulin) or an intravenous infusion of dextrose is used for treatment, but usually only if the person is unconscious. In any given incident, glucagon will only work once as it uses stored liver glycogen as a glucose source; in the absence of such stores, glucagon is largely ineffective. In hospitals, intravenous dextrose is often used.[18]

Diabetic coma

Diabetic coma is a medical emergency in which a person with diabetes mellitus is comatose (unconscious) because of one of the acute complications of diabetes:[19] [20]

  1. Severe diabetic hypoglycemia
  2. Diabetic ketoacidosis advanced enough to result in unconsciousness from a combination of severe hyperglycemia, dehydration and shock, and exhaustion
  3. Hyperosmolar nonketotic coma in which extreme hyperglycemia and dehydration alone are sufficient to cause unconsciousness.

Chronic complications

Microangiopathy

Damage to small blood arteries is the cause of what called microangiopathy, which may lead to any of these:

Macrovascular disease

Macrovascular disease leads to cardiovascular disease, to which accelerated atherosclerosis is a contributor:

Diabetes can also lead to cancer. Cancers that diabetes can lead to include:

Immune compromise

The immune response is impaired in individuals with diabetes mellitus. Cellular studies have shown that hyperglycemia both reduces the function of immune cells and increases inflammation.

Risk factors

Age

Type 2 diabetes in youth brings a much higher prevalence of complications like diabetic kidney disease, retinopathy and peripheral neuropathy than type 1 diabetes, though no significant difference in the odds of arterial stiffness and hypertension.[44]

Poor glucose control

In the early days of insulin treatment for type 1 diabetes there was much debate as to whether strict control of hyperglycaemia would delay or prevent the long-term complications of diabetes. The work of Pirart [45] suggested that microvascular complications of diabetes were less likely to occur in individuals with better glycaemic control. The issue was finally settled in 1993 with the publication of the Diabetes Control and Complications Trial.[46] In the DCCT, subjects without prior retinopathy who maintained good glycaemic control for a mean of 6.5 years were 76% less likely to develop diabetic retinopathy than subjects with less strict control. Similar results were seen for microalbuminuria and peripheral neuropathy. The benefits of strict control of blood glucose were confirmed in longer-term follow-up by the DCCT EDIC study group.[47] So far as macrovascular disease in type 1 diabetes is concerned, the same group reported improved outcomes for cardiovascular events in the group who had been managed by strict blood glucose control: in this group the incidence of any cardiovascular disease was reduced by 30% (95% CI 7, 48; P = 0.016) compared to the group with less intensive control and the incidence of major cardiovascular events (nonfatal myocardial infarction, stroke, or cardiovascular death) was reduced by 32% (95% CI −3, 56; P = 0.07).[48]

The situation regarding glycaemic control and complications in type 2 diabetes is less clear cut than for type 1, though there is evidence from the United Kingdom Prospective Diabetes Study Group that strict blood glucose control is beneficial for both microvascular and macrovascular complications. In the original study [49] a relatively modest difference in glycaemic control between the well-controlled and less well-controlled groups resulted in a 25% lower rate of microvascular complications. In follow-up studies from the same group significant relative risk reductions emerged for myocardial infarction (15%, P=0.014) and all-cause mortality (12%, P=0.007).[50]

Autoimmune processes

Research from 2007 suggested that in type 1 diabetics, the continuing autoimmune disease which initially destroyed the beta cells of the pancreas may also cause neuropathy,[51] and nephropathy.[52] In 2008 it was even suggested to treat retinopathy with drugs to suppress the abnormal immune response rather than by blood sugar control.[53]

Genetic factors

The known familial clustering of the type and degree of diabetic complications indicates that genetics play a role in causing complications:

Some genes appear to provide protection against diabetic complications, as seen in a subset of long-term diabetes type 1 survivors without complications.[59] [60]

Mechanisms

Chronic elevation of blood glucose level leads to damage of blood vessels called angiopathy. The endothelial cells lining the blood vessels take in more glucose than normal, since they do not depend on insulin. They then form more surface glycoproteins than normal, and cause the basement membrane to grow thicker and weaker. The resulting problems are grouped under "microvascular disease" due to damage to small blood vessels and "macrovascular disease" due to damage to the arteries.[61]

Studies show that DM1 and DM2 cause a change in balancing of metabolites such as carbohydrates, blood coagulation factors, and lipids, and subsequently bring about complications like microvascular and cardiovascular complications.

The role of metalloproteases and inhibitors in diabetic renal disease is unclear.[62]

Numerous researches have found inconsistent results about the role of vitamins in diabetic risk and complications.[63]

Thiamine acts as an essential cofactor in glucose metabolism,[64] therefore, it may modulate diabetic complications by controlling glycemic status in diabetic patients.[64] [65] Additionally, deficiency of thiamine was observed to be associated with dysfunction of β-cells and impaired glucose tolerance.[65] Different studies indicated possible role of thiamin supplementation on the prevention or reversal of early stage diabetic nephropathy,[66] as well as significant improvement on lipid profile.[65]

Low serum B12 level is a common finding in diabetics especially those taking Metformin or in advanced age.[67] Vitamin B12 deficiency has been linked to two diabetic complications; atherosclerosis and diabetic neuropathy.[68]

Low plasma concentrations of folic acid were found to be associated with high plasma homocysteine concentrations.[69] In clinical trials, homocysteine concentrations were effectively reduced within 4 to 6 weeks of oral supplementation of folic acid.[70] Moreover, since the activity of endothelial NO synthase enzyme might be potentially elevated by folate,[71] folate supplementation might be capable of restoring the availability of NO in endothelium,[72] therefore, improving endothelial function and reducing the risk for atherosclerosis. van Etten et al., found that a single dose of folic acid might help in reducing the risk of vascular complications and enhancing endothelial function in adults with type 2 diabetes by improving nitric oxide status.[73]

Three vitamins, ascorbic acid; α-tocopherol; and β-carotene, are well recognized for their antioxidant activities in human. Free radical-scavenging ability of antioxidants may reduce the oxidative stress and thus may protect against oxidative damage.[74] Based on observational studies among healthy individuals, antioxidant concentrations were found to be inversely correlated with several biomarkers of insulin resistance or glucose intolerance.[75]

Management

Blood pressure control

Modulating and ameliorating diabetic complications may improve the overall quality of life for diabetic patients.[76] For example, a 2008 study concluded that when elevated blood pressure was tightly controlled, diabetic related deaths were reduced by 32% compared to those with less controlled blood pressure.[1]

Vitamins

Many observational and clinical studies have been conducted to investigate the role of vitamins on diabetic complications,[77]

In the First National Health and Nutrition Examination Survey (NHANES I) Epidemiologic Follow-up Study, vitamin supplementations were associated with 24% reduction on the risk of diabetes, observed during 20 years of follow-up.[78]

Many observational studies and clinical trials have linked several vitamins with the pathological process of diabetes; these vitamins include folate,[79] thiamine,[80] β-carotene, and vitamin E,[81] C,[82] B12,[83] and D.

Vitamin D insufficiency is common in diabetics. Observational studies show that serum vitamin D is inversely associated with biomarkers of diabetes; impaired insulin secretion, insulin resistance, and glucose intolerance.[84] [85] It has been suggested that vitamin D may induce beneficial effects on diabetic complications by modulating differentiation and growth of pancreatic β-cells and protecting these cells from apoptosis, thus improving β-cells functions and survival.[84] In particular, vitamin D supplementation has been shown to have positive effects on people with type 1 diabetes.[86] [87] Vitamin D has also been suggested to act on immune system and modulate inflammatory responses by influencing proliferation and differentiation of different immune cells.[88], Moreover, deficiency of vitamin D may contribute to diabetic complications by inducing hyperparathyroidism, since elevated parathyroid hormone levels are associated with reduced β-cells function, impaired insulin sensitivity, and glucose intolerance.[89] [84] Finally, vitamin D may reduce the risk of vascular complications by modulating lipid profile.[90]

Vitamin C has been proposed to induce beneficial effects by two other mechanisms. It may replace glucose in many chemical reactions due to its similarity in structure, may prevent the non-enzymatic glycosylation of proteins,[83] and might reduce glycated hemoglobin (HbA1c) levels.[75] Secondly, vitamin C has also been suggested to play a role in lipid regulation as a controlling catabolism of cholesterol to bile acid.[83]

Notes and References

  1. Deshpande AD, Harris-Hayes M, Schootman M . Epidemiology of diabetes and diabetes-related complications . Physical Therapy . 88 . 11 . 1254–1264 . November 2008 . 18801858 . 3870323 . 10.2522/ptj.20080020 .
  2. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B . 6 . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes . The New England Journal of Medicine . 353 . 25 . 2643–2653 . December 2005 . 16371630 . 10.1056/NEJMoa052187 . 2637991 . free .
  3. The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group . Annals of Internal Medicine . 122 . 8 . 561–568 . April 1995 . 7887548 . 10.7326/0003-4819-122-8-199504150-00001 . 24754081 .
  4. Kompaniyets L, Pennington AF, Goodman AB, Rosenblum HG, Belay B, Ko JY, Chevinsky JR, Schieber LZ, Summers AD, Lavery AM, Preston LE, Danielson ML, Cui Z, Namulanda G, Yusuf H, Mac Kenzie WR, Wong KK, Baggs J, Boehmer TK, Gundlapalli AV . 6 . Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020-March 2021 . Preventing Chronic Disease . 18 . E66 . July 2021 . 34197283 . 10.5888/pcd18.210123 . 8269743 . free .
  5. Book: Gosmanov AR, Gosmanova EO, Kitabchi AE . Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State . 2000 . http://www.ncbi.nlm.nih.gov/books/NBK279052/ . Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP . 6 . Endotext . 2023-09-17 . South Dartmouth (MA) . MDText.com, Inc. . 25905280 .
  6. Sood K, Ankita S, Shah AK, Yadav BB . May 2023 . Diabetic Ketoacidosis -Review Article . Journal of Cardiovascular Disease Research.
  7. Book: Zammitt N, O'Brien A . Essentials of Kumar and Clark's Clinical Medicine . 28 June 2017 . Philadelphia . Elsevier . 978-0-7020-6604-7 . 6th.
  8. Perilli G, Saraceni C, Daniels MN, Ahmad A . March 2013 . Diabetic Ketoacidosis: A Review and Update . Current Emergency and Hospital Medicine Reports . en . 1 . 1 . 10–17 . 10.1007/s40138-012-0001-3 . 2167-4884. free .
  9. Dhatariya KK, Glaser NS, Codner E, Umpierrez GE . Diabetic ketoacidosis . Nature Reviews. Disease Primers . 6 . 1 . 40 . May 2020 . 32409703 . 10.1038/s41572-020-0165-1 . 218624258 .
  10. Umpierrez G, Korytkowski M . Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia . Nature Reviews. Endocrinology . 12 . 4 . 222–232 . April 2016 . 26893262 . 10.1038/nrendo.2016.15 . 205482047 .
  11. Book: Penman ID, Ralston S, Strachan MJ, Hobson RP . Davidson's Principles and Practice of Medicine . 2022 . Elsevier . Edinburgh . 978-0-7020-8347-1 . 24th.
  12. Pasquel FJ, Umpierrez GE . Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment . Diabetes Care . 37 . 11 . 3124–3131 . November 2014 . 25342831 . 4207202 . 10.2337/dc14-0984 .
  13. Book: Adeyinka A, Kondamudi NP . Hyperosmolar Hyperglycemic Syndrome . 2023 . http://www.ncbi.nlm.nih.gov/books/NBK482142/ . StatPearls . 2023-09-17 . Treasure Island (FL) . StatPearls Publishing . 29489232 .
  14. Web site: Hypoglycemia-Signs, Symptoms, & Treatment ADA . 2024-07-30 . diabetes.org.
  15. 2010-09-01 . Hypoglycemia in Type 1 Diabetes Mellitus . Endocrinology and Metabolism Clinics of North America . 39 . 3 . 641–654 . 10.1016/j.ecl.2010.05.003 . 0889-8529 . 2923455 . 20723825. Cryer. Philip E..
  16. Dagogo-Jack S . Philip E. Cryer, MD: Seminal Contributions to the Understanding of Hypoglycemia and Glucose Counterregulation and the Discovery of HAAF (Cryer Syndrome) . Diabetes Care . 38 . 12 . 2193–2199 . December 2015 . 26604275 . 4876742 . 10.2337/dc15-0533 .
  17. Davis. Stephen N.. Shamoon. Harry. 2003-06-02 . Hypoglycemia in diabetes . Diabetes Care . 26 . 6 . 1902–1912 . 10.2337/diacare.26.6.1902 . 0149-5992 . 12766131. Cryer. Philip E..
  18. 2011-09-06 . Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy . 4 . 337–346 . 10.2147/DMSO.S20633 . free. 1178-7007 . 3180523 . 21969805. Kedia.
  19. Web site: Diabetes Coma . Cleveland Clinic . 2019-06-21 . tertiary source.
  20. Web site: Diabetic coma . mayoclinic.org.
  21. Aliseda Pérez de Madrid D, Berástegui I . [Diabetic retinopathy] . Anales del Sistema Sanitario de Navarra . 31 . Suppl 3 . 23–34 . 2008 . 10.4321/S1137-66272008000600003 . 19169292 . free .
  22. Web site: Mailloux L . 2007-02-13 . UpToDate Dialysis in diabetic nephropathy . 2007-12-07 . UpToDate.
  23. Nagib AM, Elsayed Matter Y, Gheith OA, Refaie AF, Othman NF, Al-Otaibi T . Diabetic Nephropathy Following Posttransplant Diabetes Mellitus . Experimental and Clinical Transplantation . 17 . 2 . 138–146 . April 2019 . 30945628 . 10.6002/ect.2018.0157 . 93000559 .
  24. Dohrn MF, Winter N, Dafotakis M . [Causes, spectrum, and treatment of the diabetic neuropathy] . de . Der Nervenarzt . 91 . 8 . 714–721 . August 2020 . 32647958 . 10.1007/s00115-020-00948-3 . free .
  25. Book: Biessels GJ . Clinical Diabetes . Diabetic Encephalopathy . 2007 . http://link.springer.com/10.1007/978-1-59745-311-0_11 . Diabetic Neuropathy . 187–205 . Veves A, Malik RA . 2023-09-15 . Totowa, NJ . Humana Press . en . 10.1007/978-1-59745-311-0_11 . 978-1-58829-626-9 .
  26. Gispen WH, Biessels GJ . Cognition and synaptic plasticity in diabetes mellitus . Trends in Neurosciences . 23 . 11 . 542–549 . November 2000 . 11074263 . 10.1016/S0166-2236(00)01656-8 . 44860763 .
  27. News: Diabetes doubles Alzheimer's risk . CNN . 2011-09-19.
  28. Kobayashi S, Liang Q . Autophagy and mitophagy in diabetic cardiomyopathy . Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease . 1852 . 2 . 252–261 . February 2015 . 24882754 . 10.1016/j.bbadis.2014.05.020 . free .
  29. Web site: Erectile Dysfunction by Diabetes. live. 2 July 2016. doctor.ac. https://web.archive.org/web/20210818094817/https://www.starcarehospitals.com/blog/complication-of-diabetes/ . 2021-08-18 .
  30. Defeudis G, Mazzilli R, Tenuta M, Rossini G, Zamponi V, Olana S, Faggiano A, Pozzilli P, Isidori AM, Gianfrilli D . 6 . Erectile dysfunction and diabetes: A melting pot of circumstances and treatments . Diabetes/Metabolism Research and Reviews . 38 . 2 . e3494 . February 2022 . 34514697 . 9286480 . 10.1002/dmrr.3494 .
  31. Web site: April 18, 2016 . Diabetes Complications . Diabetes Daily.
  32. Marrakchi . M. . Dhieb . N. . Ounaissa . K. . Mehrez . A. . Boukhayatia . F. . Ben Brahim . A. . Yahyaoui . R. . Abdelsellem . H. . Amrouche . C. . 2023-10-01 . Relationship between diabetic microangiopathy and sexual dysfunction in women with type 2 diabetes . Annales d'Endocrinologie . 39e congrès de la Société Française d'Endocrinologie 2023 . 84 . 5 . 633 . 10.1016/j.ando.2023.07.358 . 0003-4266.
  33. Mealey BL . Periodontal disease and diabetes. A two-way street . Journal of the American Dental Association . 137 . Suppl . 26S–31S . October 2006 . 17012733 . 10.14219/jada.archive.2006.0404 . free .
  34. Preshaw PM, Alba AL, Herrera D, Jepsen S, Konstantinidis A, Makrilakis K, Taylor R . Periodontitis and diabetes: a two-way relationship . Diabetologia . 55 . 1 . 21–31 . January 2012 . 22057194 . 3228943 . 10.1007/s00125-011-2342-y .
  35. Scott G . The diabetic foot examination: A positive step in the prevention of diabetic foot ulcers and amputation. Osteopathic Family Physician . 5 . 2 . 73–78 . March–April 2013. 10.1016/j.osfp.2012.08.002. 72816348.
  36. Weiss JS, Sumpio BE . Review of prevalence and outcome of vascular disease in patients with diabetes mellitus . European Journal of Vascular and Endovascular Surgery . 31 . 2 . 143–150 . February 2006 . 16203161 . 10.1016/j.ejvs.2005.08.015 . free .
  37. Codner E, Merino PM, Tena-Sempere M . Female reproduction and type 1 diabetes: from mechanisms to clinical findings . Human Reproduction Update . 18 . 5 . 568–585 . 2012 . 22709979 . 10.1093/humupd/dms024 . free .
  38. Shauly-Aharonov M, Shafrir A, Paltiel O, Calderon-Margalit R, Safadi R, Bicher R, Barenholz-Goultschin O, Stokar J . 6 . Both high and low pre-infection glucose levels associated with increased risk for severe COVID-19: New insights from a population-based study . PLOS ONE . 16 . 7 . e0254847 . 22 July 2021 . 34293038 . 8297851 . 10.1371/journal.pone.0254847 . free . 2021PLoSO..1654847S .
  39. Nobs . Samuel Philip . Kolodziejczyk . Aleksandra A. . Adler . Lital . Horesh . Nir . Botscharnikow . Christine . Herzog . Ella . Mohapatra . Gayatree . Hejndorf . Sophia . Hodgetts . Ryan-James . Spivak . Igor . Schorr . Lena . Fluhr . Leviel . Kviatcovsky . Denise . Zacharia . Anish . Njuki . Suzanne . December 2023 . Lung dendritic-cell metabolism underlies susceptibility to viral infection in diabetes . Nature . en . 624 . 7992 . 645–652 . 10.1038/s41586-023-06803-0 . 1476-4687. free . 38093014 . 10733144 . 2023Natur.624..645N .
  40. Ahmed MS, Reid E, Khardori N. Respiratory infections in diabetes: Reviewing the risks and challenges. Journal of Respiratory Diseases. June 24, 2008. December 9, 2009. September 2, 2012. https://web.archive.org/web/20120902201301/http://www.consultantlive.com/diabetes/article/1145425/1403686. dead.
  41. Hsia CC, Raskin P . Lung involvement in diabetes: does it matter? . Diabetes Care . 31 . 4 . 828–829 . April 2008 . 18375433 . 10.2337/dc08-0103 . free .
  42. Mishra GP, Dhamgaye TM, Tayade BO, Amol BF, Amit S, Jasmin DM. Study of Pulmonary Function Tests in Diabetics with COPD or Asthma. Applied Cardiopulmonary Pathophysiology. December 2012. 16. 4–2012. 299–308. 13 February 2013. 9 July 2014. https://web.archive.org/web/20140709142553/http://www.applied-cardiopulmonary-pathophysiology.com/fileadmin/downloads/acp-2012-4_20121230/05_Mishra.pdf. dead.
  43. Lin EH, Rutter CM, Katon W, Heckbert SR, Ciechanowski P, Oliver MM, Ludman EJ, Young BA, Williams LH, McCulloch DK, Von Korff M . 6 . Depression and advanced complications of diabetes: a prospective cohort study . Diabetes Care . 33 . 2 . 264–269 . February 2010 . 19933989 . 2809260 . 10.2337/dc09-1068 .
  44. Dabelea D, Stafford JM, Mayer-Davis EJ, D'Agostino R, Dolan L, Imperatore G, Linder B, Lawrence JM, Marcovina SM, Mottl AK, Black MH, Pop-Busui R, Saydah S, Hamman RF, Pihoker C . 6 . Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood . JAMA . 317 . 8 . 825–835 . February 2017 . 28245334 . 5483855 . 10.1001/jama.2017.0686 .
  45. Pirart J . [Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (3rd and last part) (author's transl)] . Diabète & Métabolisme . 3 . 4 . 245–256 . December 1977 . 598565 .
  46. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C . 6 . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus . The New England Journal of Medicine . 329 . 14 . 977–986 . September 1993 . 8366922 . 10.1056/NEJM199309303291401 . 21528496 . free .
  47. Aiello LP . Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study . Diabetes Care . 37 . 1 . 17–23 . 2014 . 24356593 . 3867989 . 10.2337/dc13-2251 . DCCT EDIC Research Group . free .
  48. Gubitosi-Klu R . The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group . Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up . Diabetes Care . 39 . 5 . 686–693 . May 2016 . 26861924 . 4839174 . 10.2337/dc15-1990 . free .
  49. ((United Kingdom Prospective Diabetes (UKPDS) Study Group)) . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group . Lancet . 352 . 9131 . 837–853 . September 1998 . 9742976 . 10.1016/S0140-6736(98)07019-6 . 7019505 .
  50. https://www.dtu.ox.ac.uk/UKPDS/ UKPDS
  51. Granberg V, Ejskjaer N, Peakman M, Sundkvist G . Autoantibodies to autonomic nerves associated with cardiac and peripheral autonomic neuropathy . Diabetes Care . 28 . 8 . 1959–1964 . August 2005 . 16043739 . 10.2337/diacare.28.8.1959 . free .
  52. Ichinose K, Kawasaki E, Eguchi K . Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy . American Journal of Nephrology . 27 . 6 . 554–564 . 2007 . 17823503 . 10.1159/000107758 . free .
  53. Adams DD . Autoimmune destruction of pericytes as the cause of diabetic retinopathy . Clinical Ophthalmology . 2 . 2 . 295–298 . June 2008 . 19668719 . 2693966 . 10.2147/OPTH.S2629 . free .
  54. Foss CH, Vestbo E, Frøland A, Gjessing HJ, Mogensen CE, Damsgaard EM . Autonomic neuropathy in nondiabetic offspring of type 2 diabetic subjects is associated with urinary albumin excretion rate and 24-h ambulatory blood pressure: the Fredericia Study . Diabetes . 50 . 3 . 630–636 . March 2001 . 11246884 . 10.2337/diabetes.50.3.630 . free .
  55. Ban CR, Twigg SM . Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers . Vascular Health and Risk Management . 4 . 3 . 575–596 . 2008 . 18827908 . 2515418 . 10.2147/VHRM.S1991 . free .
  56. Tarnow L, Groop PH, Hadjadj S, Kazeem G, Cambien F, Marre M, Forsblom C, Parving HH, Trégouët D, Thévard A, Farrall M, Gut I, Gauguier D, Cox R, Matsuda F, Lathrop M, Vionnet N . 6 . European rational approach for the genetics of diabetic complications--EURAGEDIC: patient populations and strategy . Nephrology, Dialysis, Transplantation . 23 . 1 . 161–168 . January 2008 . 17704113 . 10.1093/ndt/gfm501 . free .
  57. Monti MC, Lonsdale JT, Montomoli C, Montross R, Schlag E, Greenberg DA . Familial risk factors for microvascular complications and differential male-female risk in a large cohort of American families with type 1 diabetes . The Journal of Clinical Endocrinology and Metabolism . 92 . 12 . 4650–4655 . December 2007 . 17878250 . 10.1210/jc.2007-1185 . free .
  58. Liew G, Klein R, Wong TY . The role of genetics in susceptibility to diabetic retinopathy . International Ophthalmology Clinics . 49 . 2 . 35–52 . 2009 . 19349785 . 2746819 . 10.1097/IIO.0b013e31819fd5d7 .
  59. Sun JK, Keenan HA, Cavallerano JD, Asztalos BF, Schaefer EJ, Sell DR, Strauch CM, Monnier VM, Doria A, Aiello LP, King GL . 6 . Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the joslin 50-year medalist study . Diabetes Care . 34 . 4 . 968–974 . April 2011 . 21447665 . 3064059 . 10.2337/dc10-1675 .
  60. Porta M, Toppila I, Sandholm N, Hosseini SM, Forsblom C, Hietala K, Borio L, Harjutsalo V, Klein BE, Klein R, Paterson AD, Groop PH . 6 . Variation in SLC19A3 and Protection From Microvascular Damage in Type 1 Diabetes . Diabetes . 65 . 4 . 1022–1030 . April 2016 . 26718501 . 4806664 . 10.2337/db15-1247 .
  61. Viberti GC . Increased capillary permeability in diabetes mellitus and its relationship to microvascular angiopathy . The American Journal of Medicine . 75 . 5B . 81–84 . November 1983 . 6673594 . 10.1016/0002-9343(83)90257-7 .
  62. P. Zaoui, et al, (2000) "Role of Metalloproteases and Inhibitors in the Occurrence and Prognosis of Diabetic Renal Lesions," Diabetes and Metabolism, vol. 26 (Supplement 4), p. 25
  63. Bonnefont-Rousselot D . The role of antioxidant micronutrients in the prevention of diabetic complications . Treatments in Endocrinology . 3 . 1 . 41–52 . 2004 . 15743112 . 10.2165/00024677-200403010-00005 . 35818398 .
  64. Arora S, Lidor A, Abularrage CJ, Weiswasser JM, Nylen E, Kellicut D, Sidawy AN . Thiamine (vitamin B1) improves endothelium-dependent vasodilatation in the presence of hyperglycemia . Annals of Vascular Surgery . 20 . 5 . 653–658 . September 2006 . 16741654 . 10.1007/s10016-006-9055-6 . 9028358 .
  65. Thornalley PJ . The potential role of thiamine (vitamin B1) in diabetic complications . Current Diabetes Reviews . 1 . 3 . 287–298 . August 2005 . 18220605 . 10.2174/157339905774574383 .
  66. Rabbani N, Thornalley PJ . Emerging role of thiamine therapy for prevention and treatment of early-stage diabetic nephropathy . Diabetes, Obesity & Metabolism . 13 . 7 . 577–583 . July 2011 . 21342411 . 10.1111/j.1463-1326.2011.01384.x . 11763040 .
  67. Pflipsen MC, Oh RC, Saguil A, Seehusen DA, Seaquist D, Topolski R . The prevalence of vitamin B(12) deficiency in patients with type 2 diabetes: a cross-sectional study . Journal of the American Board of Family Medicine . 22 . 5 . 528–534 . 2009 . 19734399 . 10.3122/jabfm.2009.05.090044 . free .
  68. Selhub, J., Jacques, P., Dallal, G., Choumenkovitch, S., & Rogers, G. (2008). The use of blood concentrations of vitamins and their respective functional indicators to define folate and vitamin B12 status. Food and Nutrition Bulletin, 29(s), 67–73
  69. Mangoni AA, Sherwood RA, Asonganyi B, Swift CG, Thomas S, Jackson SH . Short-term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes . American Journal of Hypertension . 18 . 2 Pt 1 . 220–226 . February 2005 . 15752950 . 10.1016/j.amjhyper.2004.08.036 . free .
  70. Mangoni AA, Jackson SH . Homocysteine and cardiovascular disease: current evidence and future prospects . The American Journal of Medicine . 112 . 7 . 556–565 . May 2002 . 12015248 . 10.1016/s0002-9343(02)01021-5 .
  71. Title LM, Ur E, Giddens K, McQueen MJ, Nassar BA . Folic acid improves endothelial dysfunction in type 2 diabetes--an effect independent of homocysteine-lowering . Vascular Medicine . 11 . 2 . 101–109 . May 2006 . 16886840 . 10.1191/1358863x06vm664oa . 8771566 .
  72. Montezano, A. C., & Touyz, R. M. (2012). Reactive oxygen species and endothelial function - role of nitric oxide synthase uncoupling and nox family nicotinamide adenine dinucleotide phosphate oxidases. Basic & Clinical Pharmacology & Toxicology, 110(1), 87–94
  73. van Etten RW, de Koning EJ, Verhaar MC, Gaillard CA, Rabelink TJ . Impaired NO-dependent vasodilation in patients with Type II (non-insulin-dependent) diabetes mellitus is restored by acute administration of folate . Diabetologia . 45 . 7 . 1004–1010 . July 2002 . 12136399 . 10.1007/s00125-002-0862-1 . free .
  74. Rahimi R, Nikfar S, Larijani B, Abdollahi M . A review on the role of antioxidants in the management of diabetes and its complications . Biomedicine & Pharmacotherapy . 59 . 7 . 365–373 . August 2005 . 16081237 . 10.1016/j.biopha.2005.07.002 .
  75. Sargeant LA, Wareham NJ, Bingham S, Day NE, Luben RN, Oakes S, Welch A, Khaw KT . 6 . Vitamin C and hyperglycemia in the European Prospective Investigation into Cancer--Norfolk (EPIC-Norfolk) study: a population-based study . Diabetes Care . 23 . 6 . 726–732 . June 2000 . 10840986 . 10.2337/diacare.23.6.726 . free .
  76. Ifeagwazi. Chuka Mike. Prince. Obot Anwanabasi. 2022-09-01 . Social support buffers the impacts of Diabetes distress on health-related quality of life among type 2 diabetic patients . Journal of Health Psychology . 27 . 10 . 2305–2317 . 10.1177/1359105320980821 . 1461-7277 . 33406922. Onu. Desmond Uchechukwu.
  77. Al-Maskari MY, Waly MI, Ali A, Al-Shuaibi YS, Ouhtit A . Folate and vitamin B12 deficiency and hyperhomocysteinemia promote oxidative stress in adult type 2 diabetes . Nutrition . 28 . 7–8 . e23–e26 . July 2012 . 22595450 . 10.1016/j.nut.2012.01.005 .
  78. Kataja-Tuomola M, Sundell JR, Männistö S, Virtanen MJ, Kontto J, Albanes D, Virtamo J . Effect of alpha-tocopherol and beta-carotene supplementation on the incidence of type 2 diabetes . Diabetologia . 51 . 1 . 47–53 . January 2008 . 17994292 . 10.1007/s00125-007-0864-0 . free .
  79. Mangoni AA, Sherwood RA, Swift CG, Jackson SH . Folic acid enhances endothelial function and reduces blood pressure in smokers: a randomized controlled trial . Journal of Internal Medicine . 252 . 6 . 497–503 . December 2002 . 12472909 . 10.1046/j.1365-2796.2002.01059.x . 9353868 . free .
  80. Karachalias N, Babaei-Jadidi R, Rabbani N, Thornalley PJ . Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes . Diabetologia . 53 . 7 . 1506–1516 . July 2010 . 20369223 . 10.1007/s00125-010-1722-z . free .
  81. Song Y, Cook NR, Albert CM, Van Denburgh M, Manson JE . Effects of vitamins C and E and beta-carotene on the risk of type 2 diabetes in women at high risk of cardiovascular disease: a randomized controlled trial . The American Journal of Clinical Nutrition . 90 . 2 . 429–437 . August 2009 . 19491386 . 2848361 . 10.3945/ajcn.2009.27491 .
  82. Ceriello A, Novials A, Ortega E, Canivell S, Pujadas G, La Sala L, Bucciarelli L, Rondinelli M, Genovese S . 6 . Vitamin C further improves the protective effect of GLP-1 on the ischemia-reperfusion-like effect induced by hyperglycemia post-hypoglycemia in type 1 diabetes . Cardiovascular Diabetology . 12 . 97 . June 2013 . 23806096 . 3699412 . 10.1186/1475-2840-12-97 . free .
  83. Afkhami-Ardekani M, Shojaoddiny-Ardekani A . Effect of vitamin C on blood glucose, serum lipids & serum insulin in type 2 diabetes patients . The Indian Journal of Medical Research . 126 . 5 . 471–474 . November 2007 . 18160753 .
  84. Takiishi T, Gysemans C, Bouillon R, Mathieu C . Vitamin D and diabetes . Endocrinology and Metabolism Clinics of North America . 39 . 2 . 419–46, table of contents . June 2010 . 20511061 . 10.1016/j.ecl.2010.02.013 .
  85. Talaei A, Mohamadi M, Adgi Z . The effect of vitamin D on insulin resistance in patients with type 2 diabetes . Diabetology & Metabolic Syndrome . 5 . 1 . 8 . February 2013 . 23443033 . 3586569 . 10.1186/1758-5996-5-8 . free .
  86. Web site: February 1, 2023 . Vitamin D and Diabetes: What's the Connection? . diabetesdaily.com.
  87. Elshaikh . 2022-10-18 . Does Vitamin D Have a Role in Diabetes? . Cureus . en . 14 . 10 . e30432. 10.7759/cureus.30432 . free. 36407246. 9671203. 2168-8184.
  88. Muthian G, Raikwar HP, Rajasingh J, Bright JJ . 1,25 Dihydroxyvitamin-D3 modulates JAK-STAT pathway in IL-12/IFNgamma axis leading to Th1 response in experimental allergic encephalomyelitis . Journal of Neuroscience Research . 83 . 7 . 1299–1309 . May 2006 . 16547967 . 10.1002/jnr.20826 . 71926561 .
  89. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD . Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels . Diabetic Medicine . 25 . 3 . 320–325 . March 2008 . 18279409 . 10.1111/j.1464-5491.2007.02360.x . free .
  90. Gannagé-Yared MH, Azoury M, Mansour I, Baddoura R, Halaby G, Naaman R . Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women . Journal of Endocrinological Investigation . 26 . 8 . 748–753 . August 2003 . 14669830 . 10.1007/bf03347358 . 30463402 .
  91. Mullan BA, Young IS, Fee H, McCance DR . Ascorbic acid reduces blood pressure and arterial stiffness in type 2 diabetes . Hypertension . 40 . 6 . 804–809 . December 2002 . 12468561 . 10.1161/01.hyp.0000039961.13718.00 . 8103446 . 10.1.1.538.5875 .
  92. Regensteiner JG, Popylisen S, Bauer TA, Lindenfeld J, Gill E, Smith S, Oliver-Pickett CK, Reusch JE, Weil JV . 6 . Oral L-arginine and vitamins E and C improve endothelial function in women with type 2 diabetes . Vascular Medicine . 8 . 3 . 169–175 . 2003 . 14989557 . 10.1191/1358863x03vm489oa . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Complications of diabetes".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.